A Harvard study published in JAMA Ophthalmology found that diabetic patients taking Semaglutide, which is the active ingredient in Ozempic, Wegovy, and Rybelsus, developed NAION at nearly five times the rate of those taking other medications over a three-year period
I like how you talked about the streetlight analogy
[1,2] More specifically, it's a GLP-1R agonist it activates the receptor, rather than inhibiting it
Here are the primary benefits that users and researchers consistently report: 1
In 2024, these medications became even more accessible and effective, with studies showing: Significant Weight Loss : Many individuals lost up to 15% or more of their body weight
But the latest clinical trial results deliver a framework for healthcare providers and their patients